[go: up one dir, main page]

WO1999021964A1 - Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon - Google Patents

Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon Download PDF

Info

Publication number
WO1999021964A1
WO1999021964A1 PCT/US1998/022478 US9822478W WO9921964A1 WO 1999021964 A1 WO1999021964 A1 WO 1999021964A1 US 9822478 W US9822478 W US 9822478W WO 9921964 A1 WO9921964 A1 WO 9921964A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
dna
mammary epithelial
fluid
losses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/022478
Other languages
English (en)
Inventor
Robert B. Dickson
Bassem R. Haddad
Stephen J. Mccormack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Priority to EP98955077A priority Critical patent/EP0973868A4/fr
Priority to AU11967/99A priority patent/AU1196799A/en
Publication of WO1999021964A1 publication Critical patent/WO1999021964A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Definitions

  • This invention is related to the detection of chromosomal changes in memory epithelial cells obtained from nipple aspirate fluid as a screening tool for premalignant and malignant breast lesions.
  • Nipple aspirate fluid is secreted continuously by the non-lactating breast and, in 50% to 70% of premenopausal women, can be aspirated through duct openings in the nipple using a simple non-invasive pump.
  • NAF is of interest because it has a relatively long retention time in the breast alveolar-ductal system, where it accumulates exfoliated mammary epithelial cells.
  • cytogenetic examination of cells found in NAF would provide a "snapshot" of the micro-environment where breast cancer originates.
  • classical cytologic assessment has been used to identify abnormalities in NAF-derived cells as an indicator of early progression toward breast cancer.
  • NAF cytology alone is not sufficiently sensitive to identify the subgroup of women who are on a progression pathway that will lead to breast cancer.
  • Atypical epithelial cells destined to progress to cancer have often accumulated a number of premalignant molecular changes. These changes are sufficiently subtle to require more sensitive, refined genetic analyses for their detection. Therefore, it is important to improve the sensitivity afforded by NAF cytology by examining these cells for chromosomal abnormalities.
  • This invention provides a method for studying chromosomal gains and losses in cells from nipple aspirate fluid comprising the steps of:
  • step 1 (1) aspirating fluid from breasts, (2) placing the samples of fluid obtained in step 1 onto dishes containing conditioned medium composed of a mixture of (a) supernatant from immortalized mammary epithelial cells and (b) mammary epithelial growth medium, (3) incubating the product of step 2 in a humidified incubator,
  • the method of the invention uses mammary epithelial cells shed into nipple aspirate fluid to detect cytogenetic abnormalities associated with the early stages of progression toward breast cancer.
  • the method of the invention is exemplified using molecular cytogenetic methods of comparative genomic hybridization (CGH) to NAF-derived mammary epithelial cells to identify chromosomal gains and losses associated with early breast cancer.
  • CGH comparative genomic hybridization
  • CGH permits the rapid screening of chromosomal imbalances within the test genomes without the need for metaphase preparations. Only DNA from the test samples is need. While CGH has been exemplified, other methods such as chip technology may also be used in the practice of the invention.
  • the typical NAF sample from a woman with no breast abnormalities contains less than 10 ductal epithelial cells.
  • Cells in the NAF are a heterogeneous cell population.
  • the epithelial cellularity of NAF increases in the presence of benign or malignant breast abnormalities, as does the likelihood that the woman will secrete NAF.
  • tumor cells are shed more readily than normal cells and probably have a selective growth advantage over normal cells. This could result in a preponderance of abnormal cells in the cultured sample. Chromosomal gains and losses, if present in these cells, can be detected by CGH.
  • NAF tends to contain small numbers of epithelial cells
  • the instant method provides means of increasing the number of available cells from a sample to 250 to 500 cells.
  • the DNA from these cells can then be isolated and amplified using means such as the universal DNA amplification procedure, degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR) .
  • DOP-PCR degenerate oligonucleotide primed polymerase chain reaction
  • the combination of culturing NAF-derived cells and use of universal DNA amplification followed by CGH or other means for detection of subtle genomic aberrations in those cells destined to progress to breast cancer can be a valuable diagnostic and screening tool.
  • a modified breast pump comprising a plastic cup attached by a short piece of flexible plastic tubing to a standard 20 ml syringe was used to obtain NAF.
  • the cup is placed over the cleansed nipple of the breast and the woman compresses her breast with both hands while the plunger of the syringe is withdrawn to 10 ml and held for 8-10 seconds.
  • Droplets of fluid that appear at the duct openings on the nipple were collected into capillary tubes. Attempts of 8- 10 seconds each were used to obtain the fluid sample.
  • Cell culture and DNA preparation were used to obtain the fluid sample.
  • NAF samples were placed on ice immediately, then transported for processing immediately (within 60 minutes of collection) .
  • Samples were plated directly onto a 12 well dish containing conditioned media.
  • the conditioned media is composed equal parts of supernatant from immortalized mammary epithelial cells and mammary epithelial growth medium (MEGM, Clonics, Inc.) to which antibiotics and an antifungal agent have been added. (Kenamycin, Gentamycin and Fungizone were used.)
  • MEGM mammary epithelial growth medium
  • the NAF cells were placed in a humidified incubator with 5% C0 2 at 37 °C. Cell culture media was added to the NAF cells once every three days. Colonies of the mammary epithelial cells from the NAF typically emerged within one to two weeks.
  • oligonucleotide primed polymerase chain reaction as described by Telenius et al. (Genes Chrom. Cancer 4: 257-263 (1992) and Geno ics 13: 718-725 (1992)) was used.
  • the amplification of very small amounts of DNA from a limited number of NAF-derived epithelial cells is possible using the methods, including the culture methods, described herein.
  • CGH is a cytogenetic technique based on quantitative two color fluorescence in situ hybridization (FISH) as described by Kallioniemi, et al. (Science 258: 818-821) and du Manoir, et al. (Hum. Genet. 90: 590-610 (1993).
  • FISH quantitative two color fluorescence in situ hybridization
  • digoxigenin d-UTP for control DNA and biotin dUTP for the test DNA digoxigenin d-UTP for control DNA and biotin dUTP for the test DNA
  • two different fluorochromes e.g, rhodamine anti-digoxigenin with red fluorescence for digoxigenin labeled control DNA and avidin-FITC with green fluorescence for biotinylated test DNA.
  • the differences in fluorescence intensities along the chromosomes on the normal metaphase reflect the copy number of corresponding sequences in the test DNA. If chromosomes or chromosomal sub-regions are present in identical copy numbers in both the reference and the test genome, the observed fluorescence is a blend of an equal contribution of red and green fluorescence.
  • chromosomes or chromosomal subregions are lost in the test genome, the resulting color is shifted to the red.
  • a gain in any chromosome or chromosomal subregion would be reflected in a more intense green staining on the homologous chromosome in the normal metaphase preparation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant d'étudier les gains et pertes chromosomiques dans des cellules issues du fluide d'aspiration du mamelon. Ce procédé comporte plusieurs opérations. L'opération (1) consiste à aspirer du fluide des seins. L'opération (2) consiste à placer les prélèvements de fluide de l'opération (1) dans des coupelles contenant un milieu conditionné. Ce milieu se compose d'un mélange (a) de fluide surnageant issu de cellules épithéliales mammaires immortalisées et (b) de milieu de culture épithélial mammaire. L'opération (3) consiste à faire incuber dans un incubateur humide le produit de l'opération (2). L'opération (4) consiste à compléter à intervalles réguliers le niveau de milieu dans les coupelles préparées dans l'opération (2), de façon à entretenir la croissance des cellules. L'opération (5) consiste à isoler les cellules des cultures. L'opération (6) consiste à préparer de l'ADN à partir de ces cellules. L'opération (7) consiste à amplifier l'ADN. L'opération (8) consiste à étiqueter une aliquote de l'ADN amplifié. L'opération (9) consiste à mettre en évidence dans l'ADN étiqueté les gains ou pertes chromosomiques.
PCT/US1998/022478 1997-10-24 1998-10-23 Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon Ceased WO1999021964A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98955077A EP0973868A4 (fr) 1997-10-24 1998-10-23 Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon
AU11967/99A AU1196799A (en) 1997-10-24 1998-10-23 Evaluation of changes in breast cells using nipple aspirate fluid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6277597P 1997-10-24 1997-10-24
US60/062,775 1997-10-24

Publications (1)

Publication Number Publication Date
WO1999021964A1 true WO1999021964A1 (fr) 1999-05-06

Family

ID=22044723

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1998/022478 Ceased WO1999021964A1 (fr) 1997-10-24 1998-10-23 Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon
PCT/US1998/022479 Ceased WO1999022217A2 (fr) 1997-10-24 1998-10-23 Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022479 Ceased WO1999022217A2 (fr) 1997-10-24 1998-10-23 Evaluation des changements des cellules du sein par utilisation du fluide d'aspiration du mamelon

Country Status (5)

Country Link
US (1) US6316189B1 (fr)
EP (1) EP0973868A4 (fr)
AU (2) AU1275399A (fr)
CA (1) CA2316179A1 (fr)
WO (2) WO1999021964A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128877B2 (en) * 1996-08-27 2006-10-31 Atossa Healthcare, Inc. Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2971700A (en) 1999-01-21 2000-08-07 Wayne State University Method and apparatus for measuring factors in mammary fluids
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
US6866994B2 (en) 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
US20030073951A1 (en) * 2001-05-30 2003-04-17 Morton Kevin B. Disposable patient interface for intraductal fluid aspiration system
US7211225B2 (en) * 2002-08-26 2007-05-01 Perceptronix Medical Inc. Filter devices for depositing material and density gradients of material from sample suspension
US7274809B2 (en) 2002-08-29 2007-09-25 Perceptronix Medical, Inc. And British Columbia Cancer Agency Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer
US7153691B2 (en) * 2002-11-13 2006-12-26 G6 Science Corp. Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (fr) * 1994-01-14 1995-07-20 Vanderbilt University Procede de detection et de traitement du cancer du sein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAAS R. A., ET AL.: "METHODS IN LABORATORY INVESTIGATION. IMMUNOMAGNETIC PURIFICATION OF HUMAN BREAST CARCINOMA CELLS ALLLOWS TUMOR-SPECIFIC DETECTION OF MULTIDRUG RESISTANCE GENE 1-MRNA BY REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION IN FINE-NEEDLE ASPIRATES.", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC., vol. 72., no. 06., 1 January 1995 (1995-01-01), The United States and Canadian Academy of Pathology, Inc., pages 760 - 764., XP002915811, ISSN: 0023-6837 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128877B2 (en) * 1996-08-27 2006-10-31 Atossa Healthcare, Inc. Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer

Also Published As

Publication number Publication date
AU1196799A (en) 1999-05-17
US6316189B1 (en) 2001-11-13
AU1275399A (en) 1999-05-17
EP0973868A1 (fr) 2000-01-26
EP0973868A4 (fr) 2003-05-28
CA2316179A1 (fr) 1999-05-06
WO1999022217A2 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
Schullerus et al. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non‐papillary renal cell carcinomas
Luk et al. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization
Poddighe et al. Interphase cytogenetics of hematological cancer: comparison of classical karyotyping and in situ hybridization using a panel of eleven chromosome specific DNA probes
Devilee et al. Detection of chromosome aneuploidy in interphase nuclei from human primary breast tumors using chromosome-specific repetitive DNA probes
Fukushige et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma
Cremer et al. Detection of chromosome aberrations in the human interphase nucleus by visualization of specific target DNAs with radioactive and non-radioactive in situ hybridization techniques: diagnosis of trisomy 18 with probe L1. 84
James Comparative genomic hybridization as a tool in tumour cytogenetics
JP2751886B2 (ja) 乳ガン細胞の検出方法
Isaacs et al. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients
US6316189B1 (en) Evaluation of changes in breast cells using nipple aspirate fluid
Karlsen et al. PCR‐RFLP studies on chromosome 3p in formaldehyde‐fixed, paraffin‐embedded cervical cancer tissues
CN112795649A (zh) 一种用于检测her2基因扩增水平的探针组及其应用
Sallinen et al. Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas
Ritterbach et al. Detection of hyperdiploid karyotypes (> 50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH)
Cunsolo et al. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status
US9617603B2 (en) Method for the urinary detection of bladder cancer
Prochazkova et al. Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T‐cell lymphoma
Roka et al. Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer
von Knobloch et al. Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer
US6432650B1 (en) Amplification of chromosomal DNA in situ
WO2002088388A1 (fr) Procede et dispositif de quantification de charges de mutation
Herrington et al. Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes
CN117625538A (zh) 人肝内胆管癌细胞系icc-x2及其应用
JP2006094733A (ja) 癌の検出方法
Ramaekers et al. Advances in the detection of ploidy differences in cancer by in situ hybridization

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998955077

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998955077

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998955077

Country of ref document: EP